Topics

Former FDA Commissioner Scott Gottlieb Forecasts Future of Biosimilars

06:00 EDT 27 Oct 2019 | OncLive

Scott Gottlieb, MD, discusses facets of biosimilar development as well as commercial and policy changes that could have the greatest impact on the use of these products in the field of oncology.

Original Article: Former FDA Commissioner Scott Gottlieb Forecasts Future of Biosimilars

NEXT ARTICLE

More From BioPortfolio on "Former FDA Commissioner Scott Gottlieb Forecasts Future of Biosimilars"

Quick Search

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...